Advertisement
Proteintech
Proteintech

The Scientist

» pharma

Most Recent

image: Endo to Pay $8 Billion for Par

Endo to Pay $8 Billion for Par

By | May 19, 2015

The deal would create one of the five biggest generic drugmakers in the U.S.

0 Comments

image: 23andMe Enters Drug Development

23andMe Enters Drug Development

By | March 12, 2015

The personal genomics firm announces plans to make medicines.

1 Comment

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: Roche Buys Biotech for $8.3B

Roche Buys Biotech for $8.3B

By | August 27, 2014

The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.

0 Comments

image: Roche Set to Buy RNAi Firm

Roche Set to Buy RNAi Firm

By | August 6, 2014

The Swiss pharmaceutical giant will reportedly pay $450 million for a Danish biotech company that develops drugs that silence microRNAs.

2 Comments

image: EMA Gearing Up for Transparency

EMA Gearing Up for Transparency

By | June 16, 2014

The European Medicines Agency is preparing for a new policy that will release rarely-seen clinical trial reports for independent scrutiny.  

0 Comments

image: Merck Snaps Up Biotech for $3.85B

Merck Snaps Up Biotech for $3.85B

By | June 10, 2014

The drug giant will acquire Cambridge, Massachusetts-based Idenix Pharmaceuticals, which is focused on developing treatments for hepatitis C.

0 Comments

image: Welcome Back, Pharmalot

Welcome Back, Pharmalot

By | June 4, 2014

The Wall Street Journal revives the popular blog covering pharmaceutical and biotech industry news.

0 Comments

image: Pharma Buyout Tabled

Pharma Buyout Tabled

By | May 27, 2014

Pfizer says it won’t continue its pursuit to purchase AstraZeneca—at least for now.

0 Comments

image: Opinion: Sexual Dysfunction Matters

Opinion: Sexual Dysfunction Matters

By | August 19, 2013

Desire and arousal disorders require the biopharmaceutical industry’s attention.

7 Comments

Advertisement

Popular Now

  1. Antibiotics and the Gut Microbiome
  2. Sex Differences in Pain Pathway
  3. The Sum of Our Parts
    Features The Sum of Our Parts

    Putting the microbiome front and center in health care, in preventive strategies, and in health-risk assessments could stem the epidemic of noncommunicable diseases.

  4. Anti-Vax Doctor Found Dead
    The Nutshell Anti-Vax Doctor Found Dead

    Police are calling the death of James Bradstreet, a physician who claimed vaccines cause autism and offered autism cures to patients, an apparent suicide.

Advertisement
Bina Technologies
Bina Technologies
Advertisement
The Scientist